Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
11.11 ^USD	-1.77%		+1.14%	-26.67%

Apr. 11	Zentalis Pharmaceuticals, Inc. Announces Executive Changes	CI
Apr. 11	Zentalis Pharmaceuticals, Inc. Announces CFO Changes	CI

Zentalis Pharmaceuticals, Inc. Announces Cease of Iris Roth as Chief Operating Officer, Effective October 10, 2023

October 06, 2023 at 05:01 pm EDT

Zentalis Pharmaceuticals, Inc. announced that Iris Roth, Ph.D., Chief Operating Officer of the Company, will depart from the Company and cease serving as Chief Operating Officer of the Company, effective October 10, 2023.

Latest news about Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. Announces Executive Changes	Apr. 11	CI
Zentalis Pharmaceuticals, Inc. Announces CFO Changes	Apr. 11	CI
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024	Apr. 02	CI
Wedbush Raises Zentalis Pharmaceuticals' PT to $15 From $12, Tweaks Financing Assumptions, Says Still on Track to Share Multiple Azenosertib Datasets in 2024, 2025; Keeps Neutral Rating	Feb. 28	MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Zentalis Pharmaceuticals Names Chief Medical Officer, Chief Business Officer	Jan. 25	MT
Zentalis Pharmaceuticals, Inc. Announces Executive Changes	Jan. 25	CI
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating	Jan. 23	MT
Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate	Jan. 08	CI
UBS Adjusts Zentalis Pharmaceuticals Price Target to $28 From $52, Maintains Buy Rating	Nov. 28	MT
Zentalis Pharmaceuticals Insider Bought Shares Worth $167,943, According to a Recent SEC Filing	Nov. 13	MT
Transcript : Zentalis Pharmaceuticals, Inc. - Special Call	Nov. 10
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ
Wedbush Downgrades Zentalis Pharmaceuticals to Neutral From Outperform After Announced Updates to Azenosertib Strategy in Platinumsensitive Ovarian Cancer; Cuts PT to $12 From $38	Nov. 08	MT
Stifel Cuts Price Target on Zentalis Pharmaceuticals to $36 From $44, Maintains Buy Rating	Nov. 07	MT
HC Wainwright Lowers Price Target on Zentalis Pharmaceuticals to $46 From $55, Maintains Buy Rating	Nov. 07	MT
Morgan Stanley Adjusts Price Target on Zentalis Pharmaceuticals to $38 From $55, Maintains Overweight Rating	Nov. 07	MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Zentalis Pharmaceuticals, Inc. Announces Executive Changes	Nov. 06	CI
Zentalis Pharmaceuticals Chief Operating Officer to Depart	23-10-09	MT
Zentalis Pharmaceuticals Insider Sold Shares Worth $106,926, According to a Recent SEC Filing	23-10-09	MT
Zentalis Pharmaceuticals Insider Sold Shares Worth $118,355, According to a Recent SEC Filing	23-10-09	MT
Zentalis Pharmaceuticals, Inc. Announces Cease of Iris Roth as Chief Operating Officer, Effective October 10, 2023	23-10-06	CI
Certain Common Stock of Zentalis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-SEP-2023.	23-09-14	CI
Certain Common Stock of Zentalis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 14-SEP-2023.	23-09-13	CI

Chart Zentalis Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Companyâs lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.11 USD

Average target price

35.6 USD

Spread / Average Target

+220.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZENTALIS PHARMACEUTICALS, INC.	-26.67%	803M
VERTEX PHARMACEUTICALS INCORPORATED	-1.65%	104B
REGENERON PHARMACEUTICALS, INC.	+6.75%	97.47B
ARGENX SE	+5.71%	22.25B
BIONTECH SE	-12.60%	21.68B
GENMAB A/S	-9.70%	18.2B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-10.17%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+6.12%	14.39B
SAREPTA THERAPEUTICS, INC.	+35.47%	12.37B

Bio Therapeutic Drugs